Contact
searchSearch
HMP Global

News

News
Chemical Engineers Receive $3.5 Million Grant to Investigate Adolescent Exposure and Opioid Addiction
11/20/2023
The National Institutes of Health’s National Institute on Drug Abuse is awarding a 5-year, $3.5 million grant to the Virginia Tech Department of Chemical Engineering’s pioneering research to understand how adolescent exposure may contribute...
The National Institutes of Health’s National Institute on Drug Abuse is awarding a 5-year, $3.5 million grant to the Virginia Tech Department of Chemical Engineering’s pioneering research to understand how adolescent exposure may contribute...
The National Institutes of...
11/20/2023
Pharmacy Learning Network
News
Debate Emerges Over Pfizer's Disclosure of Safety Signal in RSV Vaccine Trial
11/20/2023
An investigation by The BMJ has Pfizer facing criticism for failing to inform pregnant women participating in an RSV vaccine trial of the suspension of a similar GSK trial due to a safety concern regarding preterm birth.
An investigation by The BMJ has Pfizer facing criticism for failing to inform pregnant women participating in an RSV vaccine trial of the suspension of a similar GSK trial due to a safety concern regarding preterm birth.
An investigation by The BMJ has...
11/20/2023
Pharmacy Learning Network
News
Pharmacists Say Administration's Limit on PBMs Backfired
11/17/2023
According to pharmacists, the Biden administration’s first major step toward imposing limits on the pharmacy benefit managers who act as the drug industry’s price negotiators is backfiring—heavily impacting independent drugstores, which is...
According to pharmacists, the Biden administration’s first major step toward imposing limits on the pharmacy benefit managers who act as the drug industry’s price negotiators is backfiring—heavily impacting independent drugstores, which is...
According to pharmacists, the...
11/17/2023
Pharmacy Learning Network
News
Pain Injection Recalled
11/16/2023
The FDA is recalling a partial opioid agonist indicated for the management of pain severe enough to require an opioid analgesic and for which alternate treatments are inadequate.
The FDA is recalling a partial opioid agonist indicated for the management of pain severe enough to require an opioid analgesic and for which alternate treatments are inadequate.
The FDA is recalling a partial...
11/16/2023
Pharmacy Learning Network
News
Potential for Glass Particulate in Injections Prompts Recall
11/16/2023
A Class I recall has been issued for 24,900 vials of 4.2% sodium bicarbonate injection distributed by Hospira, a Pfizer company, because of the potential presence of glass particulate, according to the November 15, 2023, US Food and Drug...
A Class I recall has been issued for 24,900 vials of 4.2% sodium bicarbonate injection distributed by Hospira, a Pfizer company, because of the potential presence of glass particulate, according to the November 15, 2023, US Food and Drug...
A Class I recall has been issued...
11/16/2023
Pharmacy Learning Network
News
Antiarrhythmic Injection Under Class I Recall
11/15/2023
More than 20,000 vials of 1% lidocaine hydrochloride injection distributed by Hospira are under a Class I recall because they may contain glass particulate, according to the November 15, 2023, US Food and Drug Administration (FDA) Enforcement...
More than 20,000 vials of 1% lidocaine hydrochloride injection distributed by Hospira are under a Class I recall because they may contain glass particulate, according to the November 15, 2023, US Food and Drug Administration (FDA) Enforcement...
More than 20,000 vials of 1%...
11/15/2023
Pharmacy Learning Network
News
Balancing Potential Prevention Strategies for Respiratory Syncytial Virus With Continued Emphasis on Supportive Care as Optimal Treatment
11/15/2023
Specific therapies are lacking for treating respiratory syncytial virus (RSV), and while current prevention strategies offer great potential, supportive care remains the best treatment, according to a study published in Pathogens.
Specific therapies are lacking for treating respiratory syncytial virus (RSV), and while current prevention strategies offer great potential, supportive care remains the best treatment, according to a study published in Pathogens.
Specific therapies are lacking...
11/15/2023
Pharmacy Learning Network
News
Decreasing Trend in Emergency Department Opioid Prescribing Continues
11/14/2023
“This report, based on the most recent estimates from NHAMCS on ED visits made by adults with opioids prescribed at discharge, shows a continued decreasing trend in opioid prescription patterns within the ED setting,” researchers wrote. 
“This report, based on the most recent estimates from NHAMCS on ED visits made by adults with opioids prescribed at discharge, shows a continued decreasing trend in opioid prescription patterns within the ED setting,” researchers wrote. 
“This report, based on the most...
11/14/2023
Pharmacy Learning Network
News
Guidelines Needed to Establish Medicare Drug Pricing
11/14/2023
“By getting the math right, key stakeholders can have empirical conversations about cost and innovation and establish objective principles for pricing drugs under the new law,” wrote Dr. Gottlieb. “If drugmakers understand how federal...
“By getting the math right, key stakeholders can have empirical conversations about cost and innovation and establish objective principles for pricing drugs under the new law,” wrote Dr. Gottlieb. “If drugmakers understand how federal...
“By getting the math right, key...
11/14/2023
Pharmacy Learning Network
News
Reviewing First-Line Pharmacotherapies for Alcohol Use Disorder
11/10/2023
This systematic review and meta-analysis found that oral naltrexone and acamprosate are effective first-line pharmacotherapies for individuals with alcohol use disorder, leading to improved alcohol consumption-related outcomes compared with...
This systematic review and meta-analysis found that oral naltrexone and acamprosate are effective first-line pharmacotherapies for individuals with alcohol use disorder, leading to improved alcohol consumption-related outcomes compared with...
This systematic review and...
11/10/2023
Pharmacy Learning Network

Stay Informed & Sign Up Today

Pharmacy Learning Network Newsletter

Video Insights

Videos
David Rubin, MD, on JAK Inhibitors: Small But Mighty
11/22/2023
Dr Rubin reviews his presentation from the Advances in Inflammatory Bowel Disease regional meeting on the latest information on the safety and efficacy of Janus kinase inhibitors for the treatment of inflammatory bowel disease.
Dr Rubin reviews his presentation from the Advances in Inflammatory Bowel Disease regional meeting on the latest information on the safety and efficacy of Janus kinase inhibitors for the treatment of inflammatory bowel disease.
Dr Rubin reviews his...
11/22/2023
Pharmacy Learning Network
Videos
Advantages and Drawbacks of Lecanemab in Alzheimer Disease Treatment
11/10/2023
Dr Shulz discusses the FDA-approved lecanemab for the treatment of AD.
Dr Shulz discusses the FDA-approved lecanemab for the treatment of AD.
Dr Shulz discusses the...
11/10/2023
Pharmacy Learning Network
Videos
Immunosuppressants or Immunomodulators? Biologic Agents for Psoriasis
10/27/2023
In this exclusive interview, Dr Ronald Vender goes over the highly effective targeted biologic therapies used to treat psoriasis.
In this exclusive interview, Dr Ronald Vender goes over the highly effective targeted biologic therapies used to treat psoriasis.
In this exclusive interview, Dr...
10/27/2023
Pharmacy Learning Network
Videos
Application of Dupilumab to Pediatric Patients With Atopic Dermatitis
10/27/2023
In this feature video, Dr Abigail Cline discusses current literature to assess reported efficacies, side effects, and risks of using dupilumab to treat atopic dermatitis in pediatric patients.
In this feature video, Dr Abigail Cline discusses current literature to assess reported efficacies, side effects, and risks of using dupilumab to treat atopic dermatitis in pediatric patients.
In this feature video, Dr...
10/27/2023
Pharmacy Learning Network
Videos
Patient Considerations When Prescribing Lecanemab for Alzheimer Disease
10/06/2023
Dr Paul Schulz discusses the newly FDA-approved lecanemab for the treatment of AD.
Dr Paul Schulz discusses the newly FDA-approved lecanemab for the treatment of AD.
Dr Paul Schulz discusses the...
10/06/2023
Pharmacy Learning Network
Headshots of Chris Fausel, PharmD, MHA, BCOP; Erin Hamai Tom, PharmD, APh, MBA, BCACP; and Ryan Nix, PharmD, MMHC
Videos
Specialty Pharmacy Next: Focus on Distribution Processes, Data Utilization, New Drugs, and More
07/18/2023
In this roundtable, cochairs of Specialty Pharmacy Next gather to discuss pertinent topics on the agenda such as white and brown bagging practices and data usage for program growth, as well as who may benefit most from attending the meeting.
In this roundtable, cochairs of Specialty Pharmacy Next gather to discuss pertinent topics on the agenda such as white and brown bagging practices and data usage for program growth, as well as who may benefit most from attending the meeting.
In this roundtable, cochairs of...
07/18/2023
Pharmacy Learning Network
Videos
Leaders in Pharmacy Come Together to Discuss and Debate Oncology-Related Developments
06/28/2021
Chris Fausel, PharmD, Val Adams, PharmD, Kirollos Hanna, PharmD, and Lisa Holle, PharmD, cochairs of Great Debates and Updates Oncology Pharmacy, come together to discuss this new CPE event aimed at educating pharmacists interested in...
Chris Fausel, PharmD, Val Adams, PharmD, Kirollos Hanna, PharmD, and Lisa Holle, PharmD, cochairs of Great Debates and Updates Oncology Pharmacy, come together to discuss this new CPE event aimed at educating pharmacists interested in...
Chris Fausel, PharmD, Val Adams,...
06/28/2021
Pharmacy Learning Network
Expanded FDA Approval Improves Care Access, Rates of Flu Cases
Videos
Expanded FDA Approval Improves Care Access, Rates of Flu Cases
04/19/2021
Gregg Sylvester, MD, MPH, chief medical officer, and David Ross, vice president, commercial operations for North America, both at Seqirus, discuss the recent FDA approval for Flucelvax Quadrivalent, explain what the expanded indication means...
Gregg Sylvester, MD, MPH, chief medical officer, and David Ross, vice president, commercial operations for North America, both at Seqirus, discuss the recent FDA approval for Flucelvax Quadrivalent, explain what the expanded indication means...
Gregg Sylvester, MD, MPH, chief...
04/19/2021
Pharmacy Learning Network
Identifying Drug Diversion Differences in Retail Pharmacies Compared With Health Systems
Videos
Identifying Drug Diversion Differences in Retail Pharmacies Compared With Health Systems
12/28/2020
Tom Knight, founder and CEO, Invistics, identifies drug diversion differences in a hospital or health system versus a retail pharmacy, and explains what retail pharmacies can do to better detect and address drug diversion.
Tom Knight, founder and CEO, Invistics, identifies drug diversion differences in a hospital or health system versus a retail pharmacy, and explains what retail pharmacies can do to better detect and address drug diversion.
Tom Knight, founder and CEO,...
12/28/2020
Pharmacy Learning Network
Identifying Risks of Human Error, Workarounds in Pharmacy
Videos
Identifying Risks of Human Error, Workarounds in Pharmacy
12/22/2020
Matthew Grissinger, RPh, FISMP, FASCP, director of Error Reporting Programs, Institute for Safe Medication Practices, discusses how human error, various at-risk behaviors, as well as workarounds taken by staff members all impact outcomes and...
Matthew Grissinger, RPh, FISMP, FASCP, director of Error Reporting Programs, Institute for Safe Medication Practices, discusses how human error, various at-risk behaviors, as well as workarounds taken by staff members all impact outcomes and...
Matthew Grissinger, RPh, FISMP,...
12/22/2020
Pharmacy Learning Network

Specialties

Events

Year Round Education

HMP Global Products

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2025 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Term of Use